NCT06092268View on ClinicalTrials.gov

A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Advanced Solid Tumors
Interventions
DRUG

SHR-A2009 for injection ； Almonertinib Mesilate Tablets

"Phase IB: SHR-A2009 will be administered intravenously，Almonertinib Mesilate Tablets will be administered orally. 2 or 3 dose levels are preset in phase IB.~Phase II: 2 dose cohorts will be selected and it's randomization."

DRUG

SHR-A2009 for injection；Adebrelimab Injection

"Phase IB: SHR-A2009 and Adebrelimab will be administered intravenously. 2 dose levels are preset in phase IB.~Phase II: RPD2 will be selected to evaluate preliminary efficacy."

All Listed Sponsors
lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT06092268 - A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter